Regeneus has entered into a US$16.5m collaboration with AGC Asahi Glass (AGC) for manufacture of Progenza for the Japanese market. Regeneus and AGC have formed a 50:50 JV for clinical development and commercialisation of Progenza in Japan – we expect the JV to sub-license one or more partners to undertake clinical trials in a number of indications in Japan. We welcome the deal, which strengthens Regeneus’s balance sheet and provides significant validation for the Progenza technolo
29 Jan 2017
Japan collaboration validates Progenza
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Japan collaboration validates Progenza
Regeneus Ltd. (RGS:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
29 Jan 2017 -
Author:
Dr Dennis Hulme -
Pages:
13
Regeneus has entered into a US$16.5m collaboration with AGC Asahi Glass (AGC) for manufacture of Progenza for the Japanese market. Regeneus and AGC have formed a 50:50 JV for clinical development and commercialisation of Progenza in Japan – we expect the JV to sub-license one or more partners to undertake clinical trials in a number of indications in Japan. We welcome the deal, which strengthens Regeneus’s balance sheet and provides significant validation for the Progenza technolo